Inhibrx

Inhibrx reports positive phase 2 results for INBRX-106 in combination with pembrolizumab in head and neck cancer: confirmed objective response rate 48.3% vs. 26.5% with pembrolizumab alone. After six months, 72.4% of the combination patients were progression-free vs. 42.8% in the control group; in HPV-positive patients response rate and PFS were substantially higher (80.0% and 90.0% vs. 33.3% and 33.0%). The combination was well tolerated; Inhibrx plans to expand the phase 2 cohort by ~50 HPV-positive patients and to consult with the FDA before initiating a phase 3. In response, Inhibrx shares rose about 6%. » Plus sur de.investing.com

Inhibrx published interim results from the phase‑2 portion of the HexAgon study: the combination of INBRX-106 with pembrolizumab achieved a confirmed objective response rate of 44.0% versus 21.4% with pembrolizumab alone (absolute increase 22.6%). In the evaluable population, 11 of 25 patients in the combination arm responded, including three complete remissions, versus 6 of 28 in the control arm. Peripheral blood analyses showed up to 15‑fold increases in CD8+/CD4+ T‑cell proliferation with the combination versus up to 2.5‑fold with pembrolizumab alone; the safety profile was manageable. Inhibrx expects PFS data in Q4 2026 and plans to start the phase‑3 portion in Q3 2026. » Plus sur de.investing.com

Shares of Inhibrx Biosciences rose to $152.22, bringing market capitalization to about $1.23 billion after a year-to-date gain of more than 608%. Over the past six months the stock gained roughly 167% and is trading near its 52-week high, while InvestingPro rates the shares as overvalued relative to its fair-value estimate. The company reported interim results from the phase‑1/2 study of Ozekibart in combination with FOLFIRI in advanced colorectal cancer, showing an objective response rate of 20%, well above standard‑therapy rates. Despite the price gains, Inhibrx remains unprofitable (EPS -$9.04), and analysts such as Stifel maintain a buy rating with a $150.00 price target, highlighting the potential of INBRX-106. » Plus sur de.investing.com